Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals
Abstract While mRNA vaccines against SARS-CoV-2 are exceedingly effective in preventing symptomatic infection, their immune response features remain to be clarified. In the present prospective study, 225 healthy individuals in Japan, who received two BNT162b2 doses, were enrolled. Correlates of BNT1...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/afc0cc4016284319811206f3cc4de9a3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:afc0cc4016284319811206f3cc4de9a3 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:afc0cc4016284319811206f3cc4de9a32021-11-28T12:16:39ZCorrelates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals10.1038/s41598-021-01930-y2045-2322https://doaj.org/article/afc0cc4016284319811206f3cc4de9a32021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-01930-yhttps://doaj.org/toc/2045-2322Abstract While mRNA vaccines against SARS-CoV-2 are exceedingly effective in preventing symptomatic infection, their immune response features remain to be clarified. In the present prospective study, 225 healthy individuals in Japan, who received two BNT162b2 doses, were enrolled. Correlates of BNT162b2-elicited SARS-CoV-2-neutralizing activity (50% neutralization titer: NT50; assessed using infectious virions) with various determinants were examined and the potency of sera against variants of concerns was determined. Significant rise in NT50s was seen in sera on day 28 post-1st dose. A moderate inverse correlation was seen between NT50s and ages, but no correlation seen between NT50s and adverse effects. NT50s and SARS-CoV-2-S1-binding-IgG levels on day 28 post-1st dose and pain scores following the 2nd dose were greater in women than in men. The average half-life of NT50s was ~ 68 days, and 23.6% (49 out of 208 individuals) failed to show detectable neutralizing activity on day 150. While sera from elite-responders (NT50s > 1,500: the top 4% among the participants) potently to moderately blocked all variants of concerns examined, some sera with low NT50s failed to block the B.1.351-beta strain. Since BNT162b2-elicited immunity against SARS-CoV-2 is short, an additional vaccine or other protective measures are needed.Kenji MaedaMasayuki AmanoYukari UemuraKiyoto TsuchiyaTomoko MatsushimaKenta NodaYosuke ShimizuAsuka FujiwaraYuki TakamatsuYasuko IchikawaHidehiro NishimuraMari KinoshitaShota MatsumotoHiroyuki GatanagaKazuhisa YoshimuraShin-ichi OkaAyako MikamiWataru SugiuraToshiyuki SatoTomokazu YoshidaShinya ShimadaHiroaki MitsuyaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Kenji Maeda Masayuki Amano Yukari Uemura Kiyoto Tsuchiya Tomoko Matsushima Kenta Noda Yosuke Shimizu Asuka Fujiwara Yuki Takamatsu Yasuko Ichikawa Hidehiro Nishimura Mari Kinoshita Shota Matsumoto Hiroyuki Gatanaga Kazuhisa Yoshimura Shin-ichi Oka Ayako Mikami Wataru Sugiura Toshiyuki Sato Tomokazu Yoshida Shinya Shimada Hiroaki Mitsuya Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals |
| description |
Abstract While mRNA vaccines against SARS-CoV-2 are exceedingly effective in preventing symptomatic infection, their immune response features remain to be clarified. In the present prospective study, 225 healthy individuals in Japan, who received two BNT162b2 doses, were enrolled. Correlates of BNT162b2-elicited SARS-CoV-2-neutralizing activity (50% neutralization titer: NT50; assessed using infectious virions) with various determinants were examined and the potency of sera against variants of concerns was determined. Significant rise in NT50s was seen in sera on day 28 post-1st dose. A moderate inverse correlation was seen between NT50s and ages, but no correlation seen between NT50s and adverse effects. NT50s and SARS-CoV-2-S1-binding-IgG levels on day 28 post-1st dose and pain scores following the 2nd dose were greater in women than in men. The average half-life of NT50s was ~ 68 days, and 23.6% (49 out of 208 individuals) failed to show detectable neutralizing activity on day 150. While sera from elite-responders (NT50s > 1,500: the top 4% among the participants) potently to moderately blocked all variants of concerns examined, some sera with low NT50s failed to block the B.1.351-beta strain. Since BNT162b2-elicited immunity against SARS-CoV-2 is short, an additional vaccine or other protective measures are needed. |
| format |
article |
| author |
Kenji Maeda Masayuki Amano Yukari Uemura Kiyoto Tsuchiya Tomoko Matsushima Kenta Noda Yosuke Shimizu Asuka Fujiwara Yuki Takamatsu Yasuko Ichikawa Hidehiro Nishimura Mari Kinoshita Shota Matsumoto Hiroyuki Gatanaga Kazuhisa Yoshimura Shin-ichi Oka Ayako Mikami Wataru Sugiura Toshiyuki Sato Tomokazu Yoshida Shinya Shimada Hiroaki Mitsuya |
| author_facet |
Kenji Maeda Masayuki Amano Yukari Uemura Kiyoto Tsuchiya Tomoko Matsushima Kenta Noda Yosuke Shimizu Asuka Fujiwara Yuki Takamatsu Yasuko Ichikawa Hidehiro Nishimura Mari Kinoshita Shota Matsumoto Hiroyuki Gatanaga Kazuhisa Yoshimura Shin-ichi Oka Ayako Mikami Wataru Sugiura Toshiyuki Sato Tomokazu Yoshida Shinya Shimada Hiroaki Mitsuya |
| author_sort |
Kenji Maeda |
| title |
Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals |
| title_short |
Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals |
| title_full |
Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals |
| title_fullStr |
Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals |
| title_full_unstemmed |
Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals |
| title_sort |
correlates of neutralizing/sars-cov-2-s1-binding antibody response with adverse effects and immune kinetics in bnt162b2-vaccinated individuals |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/afc0cc4016284319811206f3cc4de9a3 |
| work_keys_str_mv |
AT kenjimaeda correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals AT masayukiamano correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals AT yukariuemura correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals AT kiyototsuchiya correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals AT tomokomatsushima correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals AT kentanoda correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals AT yosukeshimizu correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals AT asukafujiwara correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals AT yukitakamatsu correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals AT yasukoichikawa correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals AT hidehironishimura correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals AT marikinoshita correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals AT shotamatsumoto correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals AT hiroyukigatanaga correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals AT kazuhisayoshimura correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals AT shinichioka correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals AT ayakomikami correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals AT watarusugiura correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals AT toshiyukisato correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals AT tomokazuyoshida correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals AT shinyashimada correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals AT hiroakimitsuya correlatesofneutralizingsarscov2s1bindingantibodyresponsewithadverseeffectsandimmunekineticsinbnt162b2vaccinatedindividuals |
| _version_ |
1718408095798919168 |